Piper Jaffray Companies reissued their buy rating on shares of Entellus Medical, Inc. (NASDAQ:ENTL) in a research report report published on Wednesday, July 12th.

Several other equities research analysts also recently issued reports on the company. Canaccord Genuity downgraded Entellus Medical from a buy rating to a hold rating and decreased their price target for the stock from $22.00 to $18.00 in a report on Thursday, May 4th. ValuEngine downgraded Entellus Medical from a sell rating to a strong sell rating in a report on Tuesday, May 23rd. Zacks Investment Research downgraded Entellus Medical from a hold rating to a sell rating in a report on Tuesday, May 9th. William Blair reiterated an outperform rating on shares of Entellus Medical in a report on Wednesday, May 10th. Finally, BidaskClub downgraded Entellus Medical from a strong-buy rating to a buy rating in a report on Saturday, July 8th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the stock. Entellus Medical currently has an average rating of Hold and an average target price of $21.83.

Entellus Medical (NASDAQ ENTL) opened at 16.75 on Wednesday. The company has a 50 day moving average of $16.33 and a 200 day moving average of $15.03. Entellus Medical has a 1-year low of $11.47 and a 1-year high of $22.63. The company’s market capitalization is $367.09 million.

Entellus Medical (NASDAQ:ENTL) last announced its quarterly earnings results on Thursday, August 3rd. The medical technology company reported ($0.37) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by $0.03. Entellus Medical had a negative return on equity of 66.04% and a negative net margin of 41.11%. The company had revenue of $22.10 million for the quarter, compared to the consensus estimate of $21.87 million. During the same quarter last year, the company posted ($0.27) EPS. The company’s quarterly revenue was up 18.0% compared to the same quarter last year. On average, analysts predict that Entellus Medical will post ($1.35) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Entellus Medical, Inc. (ENTL) Rating Reiterated by Piper Jaffray Companies” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another site, it was illegally copied and republished in violation of United States and international copyright & trademark law. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/08/08/entellus-medicals-entl-buy-rating-reaffirmed-at-piper-jaffray-companies-updated-updated-updated.html.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Citadel Advisors LLC acquired a new position in shares of Entellus Medical during the first quarter worth about $290,000. William Blair Investment Management LLC increased its position in shares of Entellus Medical by 1,017.0% in the first quarter. William Blair Investment Management LLC now owns 390,334 shares of the medical technology company’s stock worth $5,387,000 after buying an additional 355,388 shares during the period. Frontier Capital Management Co. LLC acquired a new position in shares of Entellus Medical during the first quarter worth about $6,464,000. Renaissance Technologies LLC increased its position in shares of Entellus Medical by 23.1% in the fourth quarter. Renaissance Technologies LLC now owns 78,800 shares of the medical technology company’s stock worth $1,495,000 after buying an additional 14,800 shares during the period. Finally, Cortina Asset Management LLC boosted its position in shares of Entellus Medical by 22.6% in the first quarter. Cortina Asset Management LLC now owns 412,323 shares of the medical technology company’s stock worth $5,690,000 after buying an additional 75,879 shares in the last quarter. Hedge funds and other institutional investors own 76.84% of the company’s stock.

About Entellus Medical

Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.

Analyst Recommendations for Entellus Medical (NASDAQ:ENTL)

Receive News & Stock Ratings for Entellus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc. and related stocks with our FREE daily email newsletter.